Pieter Pannus - Infectious Diseases

Author Information

Pieter Pannus is a researcher affiliated with the SD Infectious Diseases in Humans at Sciensano, located in Ukkel, Belgium. He is also associated with the Institute for Medical Immunology and the ULB Center for Research in Immunology (U-CRI) at Université libre de Bruxelles (ULB), situated in Gosselies, Belgium. His work primarily focuses on infectious diseases, with a special emphasis on COVID-19 and related vaccines.

Research Contributions

Pieter Pannus has made significant contributions to the understanding of COVID-19, particularly focusing on the immune response to SARS-CoV-2 and vaccination efficacy. In 2022, he co-authored several studies examining the antibody response to different variants of the virus, such as Delta and Omicron, particularly in immunocompromised patients and those who have undergone allo-HCT. His research also delves into the safety and immunogenicity of reduced-dose vaccines and the hybrid immunity in specific populations like kidney transplant recipients and hemodialysis patients. His earlier work in 2021 explored the antibody response in SARS-CoV-2 naive nursing home residents, as well as the performance of rapid serological tests for exposure assessment.

Aliases

Pieter Pannus is also known by the alias P. Pannus in various publications.

Publication and Citation Metrics

Metric	Value
Total Papers	40
Total Citations	494
H-index	13

Publications:

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

DOI: 10.1016/j.ccell.2022.02.005

Year: 2022

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

DOI: 10.1038/s41541-022-00459-z

Year: 2022

Functional reprogramming of monocytes in acute and convalescent severe COVID-19 patients.

DOI: 10.1172/jci.insight.154183

Year: 2022

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial

DOI: 10.1101/2022.03.25.22272599

Year: 2022

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients

DOI: 10.3389/fimmu.2022.827242

Year: 2022

Outlining the Prior Infection with SARS-CoV-2 study (PICOV) - preliminary findings on symptoms in nursing home residents and staff.

DOI: 10.21203/RS.3.RS-310079/V1

Year: 2021

Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naiÌve residents of nursing homes

DOI: 10.1101/2021.06.08.21258366

Year: 2021

Hybrid immunity to SARS‐CoV‐2 in kidney transplant recipients and hemodialysis patients

DOI: 10.1111/ajt.16853

Year: 2021

Performance of five rapid serological tests in mild-diseased subjects using finger prick blood for exposure assessment to SARS-CoV-2

DOI: 10.1016/j.jcv.2021.104897

Year: 2021

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.

DOI: 10.1186/s13690-021-00715-z

Year: 2021

What Are Some Current Research Directions?

What are the Risks of Untreated Infections During Pregnancy?

What Role Do Respiratory Droplets Play in Super-Spreading Events?

What Are the Limitations of Inherited Immunity?

What is the Role of Vector Control in Combating Malaria?

When Are Antimalarial Drugs Used?

Can Respiratory Symptoms Be Prevented?

Are There Different Types of Salmonella?

What is the Future of Infectious Diseases Training?

How is Immunotherapy Used in Treating Infectious Diseases?

Partnered Content Networks

Relevant Topics